RECRUITING

Transcranial Direct Current Stimulation for Post-stroke Fatigue

Talk to us

Conditions

FatigueStroke Rehabilitaion

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The investigators hypothesize that delivery of anodal tDCS to the left frontal head region will reduce fatigue severity following stroke.

Official Title

Home-based Post-stroke Fatigue Treatment Using Transcranial Direct Current Stimulation (tDCS)

Quick Facts

Study Start:2023-05-23
Study Completion:2025-12
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05816603

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Male or female patients aged \>18 years
  2. * Greater than 3 months from first hemorrhagic or ischemic stroke (subacute to chronic), confirmed through neuroimaging (CT or MRI).
  3. * Fatigue severity score average \>4 (severe fatigue)
  4. * Willingness to remain stable on pharmacologic therapy through the duration of the study.
  5. * Availability of a caregiver, family member, or friend to be present during the administration of the tDCS intervention.
  1. * Metal in the head (except mouth) or implanted cranial or thoracic devices (i.e. pacemaker, DBS stimulator)
  2. * History of seizure
  3. * History of moderate to severe traumatic brain injury
  4. * A score of 10 or more on the PHQ-9 or GAD-7 scale, suggestive of moderate to severe depression/anxiety.
  5. * A score of less than 21 on the MoCA suggesting major neurocognitive disorder.
  6. * Signs of skin rash, infection, or laceration in the supraorbital region where the tDCS will be applied.
  7. * Inability to provide informed consent
  8. * Other major neurological, medical, or psychiatric illnesses that could confound results in the opinion of the site investigator.

Contacts and Locations

Study Contact

Raquel Queiruga, M.A.
CONTACT
(212) 746-1509
rqu4002@med.cornell.edu

Principal Investigator

Joan M Stilling, MD, MS
PRINCIPAL_INVESTIGATOR
Weill Medical College of Cornell University

Study Locations (Sites)

Weill Cornell Medicine, 525 E. 68th St, Baker Pavilion, F-2106
New York, New York, 10065
United States

Collaborators and Investigators

Sponsor: Weill Medical College of Cornell University

  • Joan M Stilling, MD, MS, PRINCIPAL_INVESTIGATOR, Weill Medical College of Cornell University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-05-23
Study Completion Date2025-12

Study Record Updates

Study Start Date2023-05-23
Study Completion Date2025-12

Terms related to this study

Additional Relevant MeSH Terms

  • Fatigue
  • Stroke Rehabilitaion